BeyondSpring Inc. Profile Avatar - Palmy Investing

BeyondSpring Inc.

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has co…

Biotechnology
US, New York [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of BYSI's Analysis
CIK: 1677940 CUSIP: G10830100 ISIN: KYG108301006 LEI: - UEI: -
Secondary Listings
BYSI has no secondary listings inside our databases.